Design Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Design Therapeutics, Inc. (DSGN) reported Basic Shares Outstanding (Weighted Average) of 62.51 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-03
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 62.51M shares, a 9.93% increase year-over-year.
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 61.43M shares, a 8.24% increase year-over-year.
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 58.75M shares, a 3.65% increase year-over-year.
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 56.95M shares, a 0.58% increase year-over-year.
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 57.33M shares, a 1.31% increase from fiscal 2024.
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 56.59M shares, a 1.08% increase from fiscal 2023.
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 55.98M shares, a 0.50% increase from fiscal 2022.
- Design Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 55.71M shares, a 21.27% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 62.51M shares 10-Q · filed 2026-08-03 | 61.97M shares 10-Q · filed 2026-08-03 | 60.90M shares derived: average of 3 quarters · filed 2026-08-03 | 59.91M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 61.43M shares 10-Q · filed 2026-04-28 | 60.09M shares derived: average of 2 quarters · filed 2026-04-28 | 59.05M shares derived: average of 3 quarters · filed 2026-04-28 | 58.50M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | 58.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 57.85M shares derived: average of 2 quarters · filed 2026-03-09 | 57.52M shares derived: average of 3 quarters · filed 2026-08-03 | 57.33M shares 10-K · filed 2026-03-09 |
| 2025-09-30 | 56.95M shares 10-Q · filed 2025-11-05 | 56.91M shares derived: average of 2 quarters · filed 2026-08-03 | 56.86M shares 10-Q · filed 2025-11-05 | 56.81M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | 56.86M shares 10-Q · filed 2026-08-03 | 56.81M shares 10-Q · filed 2026-08-03 | 56.77M shares derived: average of 3 quarters · filed 2026-08-03 | 56.73M shares derived: average of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | 56.76M shares 10-Q · filed 2026-04-28 | 56.72M shares derived: average of 2 quarters · filed 2026-04-28 | 56.69M shares derived: average of 3 quarters · filed 2026-04-28 | 56.65M shares derived: average of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | 56.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 56.65M shares derived: average of 2 quarters · filed 2026-03-09 | 56.62M shares derived: average of 3 quarters · filed 2026-03-09 | 56.59M shares 10-K · filed 2026-03-09 |
| 2024-09-30 | 56.62M shares 10-Q · filed 2025-11-05 | 56.59M shares derived: average of 2 quarters · filed 2025-11-05 | 56.56M shares 10-Q · filed 2025-11-05 | 56.44M shares derived: average of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | 56.56M shares 10-Q · filed 2025-08-07 | 56.52M shares 10-Q · filed 2025-08-07 | 56.38M shares derived: average of 3 quarters · filed 2025-08-07 | 56.28M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 56.49M shares 10-Q · filed 2025-05-07 | 56.29M shares derived: average of 2 quarters · filed 2025-05-07 | 56.19M shares derived: average of 3 quarters · filed 2025-05-07 | 56.13M shares derived: average of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | 56.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 56.04M shares derived: average of 2 quarters · filed 2025-03-10 | 56.01M shares derived: average of 3 quarters · filed 2025-03-10 | 55.98M shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 55.99M shares 10-Q · filed 2024-11-07 | 55.97M shares derived: average of 2 quarters · filed 2024-11-07 | 55.95M shares 10-Q · filed 2024-11-07 | 55.93M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 55.95M shares 10-Q · filed 2024-08-05 | 55.93M shares 10-Q · filed 2024-08-05 | 55.91M shares derived: average of 3 quarters · filed 2024-08-05 | 55.88M shares derived: average of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | 55.91M shares 10-Q · filed 2024-05-08 | 55.89M shares derived: average of 2 quarters · filed 2024-05-08 | 55.85M shares derived: average of 3 quarters · filed 2024-05-08 | 55.81M shares derived: average of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | 55.87M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 55.82M shares derived: average of 2 quarters · filed 2024-03-19 | 55.77M shares derived: average of 3 quarters · filed 2024-03-19 | 55.71M shares 10-K · filed 2024-03-19 |
| 2022-09-30 | 55.78M shares 10-Q · filed 2023-11-13 | 55.73M shares derived: average of 2 quarters · filed 2023-11-13 | 55.65M shares 10-Q · filed 2023-11-13 | 55.61M shares derived: average of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | 55.67M shares 10-Q · filed 2023-08-14 | 55.59M shares 10-Q · filed 2023-08-14 | 55.55M shares derived: average of 3 quarters · filed 2023-08-14 | 55.45M shares derived: average of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | 55.51M shares 10-Q · filed 2023-05-09 | 55.49M shares derived: average of 2 quarters · filed 2023-05-09 | 55.38M shares derived: average of 3 quarters · filed 2023-05-09 | 55.30M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 55.47M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 55.31M shares derived: average of 2 quarters · filed 2023-03-14 | 55.23M shares derived: average of 3 quarters · filed 2023-03-14 | 45.94M shares 10-K · filed 2023-03-14 |
| 2021-09-30 | 55.16M shares 10-Q · filed 2022-11-03 | 55.12M shares derived: average of 2 quarters · filed 2022-11-03 | 42.76M shares 10-Q · filed 2022-11-03 | |
| 2021-06-30 | 55.08M shares 10-Q · filed 2022-08-08 | 36.46M shares 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |